CPP-115 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cocaine Dependency
Conditions
Cocaine Dependency
Trial Timeline
Dec 1, 2011 → Aug 1, 2012
NCT ID
NCT01493596About CPP-115 + Placebo
CPP-115 + Placebo is a phase 1 stage product being developed by Catalyst Pharmaceuticals for Cocaine Dependency. The current trial status is completed. This product is registered under clinical trial identifier NCT01493596. Target conditions include Cocaine Dependency.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01493596 | Phase 1 | Completed |
Competing Products
13 competing products in Cocaine Dependency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy | Johnson & Johnson | Phase 3 | 77 |
| Topiramate | Johnson & Johnson | Phase 2 | 52 |
| quetiapine | AstraZeneca | Approved | 85 |
| quetiapine fumarate + Matched Placebo | AstraZeneca | Pre-clinical | 23 |
| AFQ056 + Placebo | Novartis | Phase 1 | 33 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| ALKS 33-BUP + ALKS 33 + Placebo | Alkermes | Phase 1 | 30 |
| VIVITROL (Naltrexone extended-release injectable suspension) + Placebo | Alkermes | Phase 2 | 49 |
| vigabatrin + placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| Vigabatrin + Matching Placebo | Catalyst Pharmaceuticals | Phase 2/3 | 60 |
| Vigabatrin + Placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| TNX-1300 | Tonix Pharmaceuticals | Phase 2 | 44 |
| TNX-1300 (Injection) + Placebo (Injection) | Tonix Pharmaceuticals | Phase 2 | 44 |